Clinical and immunological features among patients with and without Sjögren syndrome (SS). Data are n (%) unless otherwise specified.
| Variables | SS, n = 65 | No SS, n = 149 | p |
|---|---|---|---|
| Age, yrs, mean ± SD | 51.8 ± 13.8 | 46.8 ± 15.1 | 0.02 |
| Women | 65 (100) | 135 (90.6) | 0.01 |
| Oral symptoms | 37 (56.9) | 26 (17.4) | < 0.0001 |
| Ocular symptoms | 44 (67.7) | 35 (23.5) | < 0.0001 |
| Parotid enlargement | 8 (12.3) | 2 (1.3) | 0.001 |
| Schirmer-I test | 43 (66.2) | 49 (32.9) | < 0.0001 |
| Wafer test | 60 (92.3) | 79 (53) | < 0.0001 |
| Keratoconjuctivitis sicca | 51/64 (79.6) | 43/94 (45.7) | < 0.0001 |
| NSWSF < 0.1 ml/min | 61 (93.8) | 57/122 (46.7) | < 0.0001 |
| Focal sialadenitis | 31/42 (73.8) | 0/17 (0) | < 0.0001 |
| RF | 28 (43.1) | 49 (32.9) | 0.15 |
| ANA ≥ 1:320 | 32 (49.2) | 85 (57) | 0.29 |
| ANA ≥ 320 and RF | 13 (20.3) | 21 (11.1) | 0.30 |
| AFA-IgA | 44 (67.7) | 94 (63.1) | 0.51 |
| AFA-IgG | 20 (30.8) | 48 (32.2) | 0.83 |
| Median AFA-IgA, U/ml (range) | 5.8 (4.3–48.5) | 5.7 (4–48) | 0.50 |
| Median AFA-IgG, U/ml (range) | 5.4 (4.3–10.9) | 5.5 (4.3–17.9) | 0.25 |
| RF and AFA-IgA | 22 (33.8) | 35 (23.5) | 0.11 |
| ANA ≥ 1:320 plus AFA-IgA | 25 (38.5) | 54 (36.2) | 0.75 |
NWSFS: nonstimulated whole salivary flow rate; RF: rheumatoid factor; ANA: antinuclear antibodies; AFA: anti-α-fodrin antibodies.